DIA:MILDiaSorin S.p.A. Analysis

DiaSorin is trading at €66.5, which sits below its 20‑day SMA of €67.94 but above the 50‑day SMA of €64.70, indicating mixed short‑term momentum. The RSI of 48 and a bearish MACD histogram reinforce a near‑neutral but slightly downside bias, while the stock remains comfortably above the identified support at €64.5. Recent Q1 2026 results missed forecasts, with revenue down 3% on a constant‑currency basis and forex headwinds cited, prompting a modest dip in the share price. Despite the earnings miss, the forward EPS of €4.32 suggests a strong earnings rebound, reflected in a forward P/E of 15.4 versus a trailing P/E of 25.3 and an industry average of 24.8. The DCF fair value of €47.2 is well below the current price, flagging the stock as overvalued in absolute terms, though the upside/downside metric shows only a ~5% premium. Dividend yield stands at 1.95% with a payout ratio near 45%, indicating sustainable income. Volatility is elevated at 41% over the past 30 days, but beta is low (≈0.16), implying limited market‑wide systematic risk. The Fear & Greed Index at “Extreme Greed” reflects strong market optimism that may be outpacing fundamentals. Overall, the company shows solid gross margins (65%) and operating margins (20.6%) but faces revenue contraction and moderate debt levels (DE/Equity ~47%). The upcoming LIAISON NES platform could provide a catalyst for medium‑term growth, yet valuation compression appears necessary before a clear upside emerges.